

CLINICAL INQUIRIES

What is the most effective treatment for tinea pedis (athlete's foot)?

J Fam Pract. 2002 January;51(1):15-22

Author(s): Tsveti Markova, MD

Tsveti Markova, MD

Wayne State University Expert literature search by E. Diane Johnson, MLS

**EVIDENCE-BASED ANSWER**

Topical therapy is effective for tinea pedis. Topical terbinafine has a 70% cure rate, is available over the counter (OTC), and requires only 1 to 2 weeks of therapy. Two other OTC topicals, tolnaftate and miconazole, require 2 to 4 weeks to achieve slightly lower cure rates, but are considerably less expensive. (Grade of recommendation: A)

The most effective treatment for tinea pedis is oral terbinafine 250 mg twice a day for 2 weeks (94% clinical cure rate). However, oral terbinafine is expensive and not approved for this indication. Oral therapy may be required for patients with hyperkerototic soles, severe disease, topical therapy failure, chronic infection or immunosuppression. (Grade of recommendation: B, based on small randomized controlled trials [RCTs] with limited head-to head comparisons of drugs)

[MD-IQ QUIZ: HCV: Testing & diagnosis](#)

SPONSORED

The End of the Wet Mount: An Update on Guidelines and Technology in the Diagnosis and Treatment of *Trichomonas vaginalis*

Funding for graphics and content dissemination provided by Hologic. This supplement was submitted by ReachMD.

Evidence summary

The Cochrane Database of Systemic Reviews^{1,2} reported 72 placebo-controlled trials of topical agents that yielded the following cure rates: undecenoic acid, 72%; allylamines (terbinafine, naftifine, butenafine), 70%; tolnaftate, 64%; azoles (miconazole, clotrimazole, ketoconazole, econazole, oxiconazole), 47%. A meta-analysis of 11 RCTs suggests that allylamines are slightly more effective than azoles.

Orally administered antifungal agents are expensive and can have systemic side effects. Griseofulvin and ketoconazole are approved for oral therapy, but product labels clearly state that they should be used only after topical agents have failed. Griseofulvin has been used for more than 30 years, is well tolerated, and efficacious in treating dermatomycoses in the range of 60%.³ Ketoconazole's cure rate is similar, but its use in cutaneous infections is limited by multiple drug interactions and serious side effects. Three placebo-controlled RCTs of itraconazole of varying doses and duration of treatment suggested favorable clinical cure of moccasin-type tinea pedis (51%-85%). The most effective itraconazole regimen was 200 mg twice daily for 1 week. In a large double-blind multicenter study of all forms of tinea pedis, De Keyser et al⁴ compared 2 weeks of terbinafine at 250 mg/day to 2 weeks of itraconazole at 100 mg/day. After 8 weeks they found terbinafine superior to itraconazole for clinical cure (94.1% vs 72.4%). In a single multicenter open study the cure rate for fluconazole 150 mg was 77% when used once weekly for 3 weeks. See [Table 1](#) for summary.

TABLE
RECOMMENDED TOPICAL TREATMENTS FOR TINEA PEDIS

Expand table

Drug	Cure Rates, %	Form	Frequency and duration of treatment*	Comments
Miconazole (Micatin)	47	2% lotion, spray, cream, powder	BID for 2-4 weeks	Inexpensive, OTC
Terbinafine (Lamisil)	70	1% cream, solution, spray	BID for 1-2 weeks	Shorter length of treatment, OTC
Naftifine (Naftin)	70	1% gel, cream	QD for 2-4 weeks	Once a day, Rx
Butenafine (Mentax)	70	1% cream	QD for 4 weeks	Once a day, Rx
Tolnaftate (Tinactin, Altate)	64	1% powder, spray, cream	BID for 2-4 weeks	Inexpensive, OTC

Rx denotes prescription; OTC, over the counter; BID, twice a day; QD, every day.
*Frequency and duration of treatment varies according to the type of tinea pedis.

Recommendations from others

American Academy of Dermatology Guidelines⁵ recommend topical therapy for initial treatment of tinea pedis. Oral therapy may be required to treat patients with hyperkeratotic soles, disabling or extensive disease, topical therapy failure, chronic infection, or immunosuppression. Surgical therapy is not indicated.

Evidence-based answers from the Family Physicians Inquiries Network

DERMATOLOGY



References

1. Crawford F, Hart R, Bell-Syer S, Togerson D, Young P, Russell I. Cochrane Review. In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.
2. Hart R, Sally E, Bell-Syer S, Crawford F, Togerson D, Young P, Russell I. *BMJ* 1999;319:79-82.
3. Pierard G, Arrese J, Pierrard-Franchimont C. *Drugs* 1996;52:209.-
4. De Keyser P, De Backer M, Massart DL, Westelnick KJ. *Br J Dermatol* 1994;130:22-5.
5. Drake LA, Dinehart SM, Farmer ER, et al. *J Am Acad Dermatol* 1996;34:282-6.

Current Issue